Login to Your Account

Aducanumab, AD still golden for Biogen Idec in updated phase I findings

By Marie Powers
News Editor

Friday, March 20, 2015

It's increasingly difficult to generate a big move in shares of a big biotech, but Alzheimer's disease did the trick again for Biogen Idec Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription